CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 87 enrolled
Drug / intervention
Bosutinibdrug
Likely dose
Bosutinib 100mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02546375
NCT02546375N/ACompleted
CompareCT.gov

A RETROSPECTIVE OBSERVATIONAL RESEARCH STUDY TO DESCRIBE THE REAL WORLD USE OF BOSUTINIB IN THE UK AND NETHERLANDS

Pfizer·observational·Posted Sep 10, 2015·Updated Oct 3, 2023

In Brief

An observational study evaluating Bosutinib for Chronic Myeloid Leukaemia. Completed, enrolled 87 participants across 3 sites.

Detailed Summary

The purpose of this study is to describe the efficacy and safety of bosutinib in patients with chronic myeloid leukaemia used in a real world setting

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Myeloid Leukaemia
CountriesUnited Kingdom
CollaboratorspH Associates

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 10, 2015
Enrollment StartJul 15, 2015
Primary CompletionJan 16, 2017
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 10.8 years ago

Interventions

Bosutinibdrug

Bosutinib 100mg film-coated tablets; Bosutinib 500mg film-coated tablets Dosage as prescribed at treating institution; (observational study)